Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
Article
Beckers, Thomas, Mahboobi, Siavosh, Sellmer, Andreas, Winkler, Matthias, Eichhorn, Emerich, Pongratz, Herwig, Maier, Thomas, Ciossek, Thomas, Baer, Thomas, Kelter, Gerhard, Fiebig, Heinz-Herbert and Schmidt, Mathias (2012) Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. MedChemComm 3 (7), p. 829.Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | MedChemComm | ||||
| Publisher | ROYAL SOC CHEMISTRY | ||||
| Place of Publication | CAMBRIDGE | ||||
| Volume | 3 | ||||
| Number of Issue or Book Chapter | 7 | ||||
| Page Range | p. 829 | ||||
| Date | 2012 | ||||
| Date of publication | 19 Dec 2024 09:39 | ||||
| Institutions | Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry I (Prof. Elz) | ||||
| Identification Number |
| ||||
| Keywords | CELL LUNG-CANCER; PHASE-II TRIAL; POTENT INHIBITORS; DERIVATIVES; MUTATIONS; GEFITINIB; LAPATINIB; ACIDS; ASSAY; | ||||
| Dewey Decimal Classification | 600 Technology > 615 Pharmacy | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 63616 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric